InfuSystem (NYSE:INFU) Stock Rating Lowered by StockNews.com

InfuSystem (NYSE:INFU) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.

InfuSystem Price Performance

Shares of InfuSystem stock opened at $6.11 on Thursday. The stock has a market capitalization of $129.92 million, a P/E ratio of 101.85 and a beta of 1.75. InfuSystem has a one year low of $5.74 and a one year high of $9.97. The business’s 50 day simple moving average is $7.96 and its two-hundred day simple moving average is $7.60. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59.

Institutional Investors Weigh In On InfuSystem

A number of large investors have recently made changes to their positions in INFU. First Eagle Investment Management LLC grew its position in shares of InfuSystem by 25.9% in the 4th quarter. First Eagle Investment Management LLC now owns 908,371 shares of the company’s stock worth $7,676,000 after buying an additional 186,668 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of InfuSystem by 283.5% in the 4th quarter. JPMorgan Chase & Co. now owns 59,662 shares of the company’s stock worth $504,000 after buying an additional 44,106 shares during the last quarter. Marshall Wace LLP boosted its position in shares of InfuSystem by 150.3% during the fourth quarter. Marshall Wace LLP now owns 53,315 shares of the company’s stock valued at $451,000 after purchasing an additional 32,015 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of InfuSystem by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 456,043 shares of the company’s stock valued at $3,853,000 after purchasing an additional 21,697 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of InfuSystem by 300.5% during the third quarter. Barclays PLC now owns 28,597 shares of the company’s stock valued at $192,000 after purchasing an additional 21,457 shares in the last quarter. 71.13% of the stock is currently owned by institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.